Navigation Links
Aventis Pays More Than $190 Million to Settle Drug Pricing Fraud Matters
Date:9/10/2007

WASHINGTON, Sept. 10 /PRNewswire-USNewswire/ -- Aventis Pharmaceuticals Inc. has paid the United States and a number of states, as well as the District of Columbia, over $190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company's alleged fraudulent pricing and marketing of drugs, the Justice Department announced today. Aventis is now known as sanofi-aventis U.S. Inc. and sanofi-aventis U.S. LLC.

Aventis, one of the world's largest pharmaceutical manufacturers, has agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting. The government alleged that the pharmaceutical company engaged in a scheme to set and maintain fraudulent and inflated prices for Anzemet knowing that federal health care programs established reimbursement rates based on those prices.

The United States alleged that Aventis used the difference between the inflated prices that it reported, which were used by federal programs to set reimbursement rates for health care providers, and the actual prices for the drugs charged to its customers in order to market, promote and sell Anzemet to existing and potential customers.

The difference between the reimbursement rate of the federal health care programs and the actual price paid by health care providers is commonly known as the "spread." The larger the spread on a drug, the larger the profit or return on investment for the provider. Because reimbursement from federal programs was based on the fraudulent, inflated prices, the United States contended that Aventis caused false and fraudulent claims to be submitted to federal health care programs.

"Marketing drugs to doctors based on potential profits undermines confidence in the integrity of our health care system because it treats beneficiaries like commodities instead of patients," said Assistant Attorney General Peter D. Keisler. "The Justice Department will continue to hold drug companies accountable for fraudulent pricing schemes designed to give windfalls to drug companies and doctors at the expense of federal health care programs for the poor and the elderly."

The investigation commenced after the filing of a False Claims Act suit by Ven-A-Care of the Florida Keys Inc., a home-infusion company. The Act allows for private persons to file a qui tam or whistleblower suit on behalf of the government. If the government is successful in resolving or litigating its claims, the whistleblower may receive a share of the recovery. As part of this settlement, the Ven-A-Care whistleblowers will receive approximately $32 million as their share of the settlement.

"Again, a corporation has been caught fraudulently inflating the cost of a drug used primarily to reduce the side effects of cancer treatments without regard to the increased costs borne by government health care programs or elderly and indigent patients," said U.S. Attorney R. Alexander Acosta of the Southern District of Florida. "Corporations cannot continue to mislead the government into paying vastly exaggerated prices by exploiting a health care system based on trust and fair play."

As part of a condition for continuing to work with providers who do business with the Medicare and Medicaid programs, Aventis agreed to enter into a Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services that, among other things, will require the company to report accurate average sales prices and average manufacturer's prices for its drugs covered by Medicare and other federal health care programs.

"Fraudulent drug pricing and marketing schemes divert scarce Medicare and Medicaid resources away from patient care," said Daniel R. Levinson, HHS Inspector General. "One of OIG's top priorities is to root out pharmaceutical fraud and hold companies liable for their actions."

"One of the essential elements in administering federal health programs is the need to protect taxpayers and the millions of elderly and low-income Americans who depend on these programs," said Kerry Weems, Acting Administrator for the Centers of Medicare and Medicaid Services. "This settlement reinforces our commitment to protect the integrity of Medicare and Medicaid."

Of the more than $190 million settlement, the federal recovery is $179,787,726, and the states' and District of Columbia's recovery for their share of Medicaid is $10,645,600.

The investigation was conducted by the Civil Division of the Department of Justice, the U.S. Attorney's Offices for the Southern District of Florida and the District of Massachusetts, the Office of Inspector General for the Department of Health and Human Services, the Office of Program Integrity of TRICARE Management Activity, and the National Association of Medicaid Fraud Control Units.

http://www.USDOJ.gov


'/>"/>
SOURCE U.S. Department of Justice
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Gives Green Signal To Sanofi-Aventis SAs Cancer Drug Taxotere
2. Sanofi-Aventis sets the ball rolling for trials of H7N1 bird flu vaccine
3. Sanofi-Aventis Allows Thais To Make Plavix
4. Drug May Make Breathing Easier for Millions
5. Hundred million dollar gift for malaria institute
6. George Bush pledges 200 million dollars for AIDS relief
7. Over Six Million HIV Infected People In South Africa- Finds A Survey
8. Hope for 11 million children facing death from illnesses
9. The forgotten epidemic killing millions
10. WHO and UNAIDS unveil plan to get 3 million AIDS patients on treatment by 2005
11. Tanzanian Government Sanctions $20 Million For AIDS Arug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... Chandler, AZ (PRWEB) , ... May 06, 2016 ... ... No Greater Odds, are scheduled to provide a unique keynote address at the ... documentary follows the inspirational stories of five community college students. Their stories—of complicated ...
(Date:5/6/2016)... Milford, PA (PRWEB) , ... May 06, 2016 ... ... CoolSculpting does to reduce fat areas around the body, is the most ... The survey results just released make perfect sense to cosmetic surgeon Dr. Richard ...
(Date:5/6/2016)... ... ... Canadian author Mark Black is a speaker, author, and life strategy coach who ... … with the help of his publisher Strategic Book Group and its subsidiary Publish ... bed waiting for a miracle: He needed a heart and double-lung transplant. From this came ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... Sovaldi, which made headlines mostly for its cost despite its potential to wipe ... questions surrounding the drug—part of a class called direct-acting antivirals (DAAs)—have created fallout ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, Inc. co-founder, ... BlueShield and Former Principal Deputy Administrator at Centers for Medicare and Medicaid Services ... Ondra, MD, Chief Medical Officer at Health Care Service Corporation (Blue Cross and ...
Breaking Medicine News(10 mins):
(Date:5/6/2016)... 6, 2016 Appoints Susanta ... its Application to Drug Development Including Development of Radiopharmaceuticals ... the life sciences consulting firm, today announced that it ... Associate Partner in its Cambridge, MA ... PhD, in the firm,s Medical Imaging consulting practice and ...
(Date:5/5/2016)... reported initial promising results in animal trials of its Zika vaccine candidates. ... ... ... ... analysis identified the highest gene Replikin Counts in Zika history back to 1946 (1). ...
(Date:5/5/2016)... DUBLIN , May 5, 2016 Endo International ... the appointment of Douglas S. Ingram , former president ... and Todd B. Sisitsky , managing partner of TPG ... immediately. "Endo recently ... best complement, enhance and expand the Board,s capabilities. Doug and ...
Breaking Medicine Technology: